Caelum Biosciences, Inc.
https://www.caelumbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Caelum Biosciences, Inc.
AstraZeneca Goes All In On AL Amyloidosis With Caelum Acquisition
AstraZeneca’s recently-acquired Alexion unit is paying $150m upfront to buy the remainder of Caelum Biosciences and its late-stage therapy for light chain amyloidosis, a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice